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Background: The AKT/mammalian target of rapamycin (mTOR) signaling pathway is regulated by 17α-estradiol (E2)
signaling and mediates E2-induced proliferation and progesterone receptor (PgR) expression in breast cancer.
Methods and results: Here we use deep sequencing analysis of previously published data from The Cancer
Genome Atlas to demonstrate that expression of a key component of mTOR signaling, rapamycin-insensitive
companion of mTOR (Rictor), positively correlated with an estrogen receptor-α positive (ERα+) breast tumor signature.
Through increased microRNA-155 (miR-155) expression in the ERα+ breast cancer cells we demonstrate repression
of Rictor enhanced activation of mTOR complex 1 (mTORC1) signaling with both qPCR and western blot.
miR-155-mediated mTOR signaling resulted in deregulated ERα signaling both in cultured cells in vitro and in
xenografts in vivo in addition to repressed PgR expression and activity. Furthermore we observed that miR-155
enhanced mTORC1 signaling (observed through western blot for increased phosphorylation on mTOR S2448) and
induced inhibition of mTORC2 signaling (evident through repressed Rictor and tuberous sclerosis 1 (TSC1) gene
expression). mTORC1 induced deregulation of E2 signaling was confirmed using qPCR and the mTORC1-specific
inhibitor RAD001. Co-treatment of MCF7 breast cancer cells stably overexpressing miR-155 with RAD001 and E2
restored E2-induced PgR gene expression. RAD001 treatment of SCID/CB17 mice inhibited E2-induced tumorigenesis
of the MCF7 miR-155 overexpressing cell line. Finally we demonstrated a strong positive correlation between Rictor
and PgR expression and a negative correlation with Raptor expression in Luminal B breast cancer samples, a breast
cancer histological subtype known for having an altered ERα-signaling pathway.
Conclusions: miRNA mediated alterations in mTOR and ERα signaling establishes a new mechanism for altered
estrogen responses independent of growth factor stimulation.
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An important downstream mediator of growth factor
signaling is mammalian target of rapamycin (mTOR).
mTOR is a serine/threonine kinase which belongs to the
family of phosphatidylinositol 3-kinase-related kinase
protein family [1]. As a regulator of gene translation,
mTOR signaling is capable of eliciting a multitude of cel-
lular responses including the regulation of cell growth,* Correspondence: mburow@tulane.edu
1Department of Medicine-Section of Hematology and Medical Oncology,
Tulane University, New Orleans, LA, USA
2Department of Pharmacology, Tulane University, New Orleans, LA, USA
Full list of author information is available at the end of the article
© 2014 Martin et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.proliferation, motility, autophagy, metastasis, and survival.
mTOR activation occurs through signaling pathways regu-
lated by insulin like growth factor (IGF), insulin, and nu-
trient signals [2-5]. The specific effects exerted by mTOR
signaling are dependent on the activation of the mTOR
complexes mTORC1 and 2, which form intricate negative
and positive feedback loops [1,4]. mTORC1 is a key trans-
lational regulator of proteins associated with cell prolifera-
tion, metabolism, and growth [1]. The main components
of mTORC1 are comprised of regulatory associated pro-
tein of TOR (Raptor), proline-rich AKT substrate 40 kDA
(PRAS40), Dep domain containing mTOR-interactingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[1,4,6]. Translation of pro-proliferative and cell growth
proteins is induced by mTOR through inhibition of 4E-
BP1 and activation of S6K1. mTORC2 is composed of
mTOR, mLST8, Sin1, PRR5, Deptor, and Rictor [1,4,7].
Interestingly, many of the inhibitors of mTORC1 signaling
are activators of mTORC2 signaling. For instance TSC1/
TSC2 inhibits mTORC1 signaling through the inhibition
of the mTOR activator Ras Homolog Enriched In Brain
(Rheb); however, TSC1/TSC2 has been demonstrated to
activate mTORC2 signaling through direct contact with
mTORC2 [7,8]. In fact, clinical tumor samples demon-
strating a loss of functional TSC1/TSC2 also showed loss
of mTORC2 function [9]. In tumor samples, loss of TSC1/
TSC2 function resulted in subsequent loss of mTORC2
activity and mTORC1 hyperactivation [10].
mTOR signaling activation by the IGF induced PI3K/
AKT pathway has been well described. Crosstalk be-
tween mTOR signaling and a number of other important
cancer associated signaling pathways, including AMPK/
p53, MAPK/ERK, and estrogen receptor-α (ERα) path-
ways were recently reported [11,12]. In breast cancer,
ERα/mTOR crosstalk is an important indicator of hor-
mone receptor status, as IGF-mediated mTORC1 activa-
tion repressed progesterone receptor (PgR) expression in
the ER+/PgR− breast cancer cell phenotype. This has
been characterized by enhanced IGF/mTOR signaling
[13,14]. In addition to regulation of PgR expression, one
effector of mTOR signaling, S6 kinase 1 (S6K1), was
shown to interact and phosphorylate ERα at serine 167
(S167) following IGF stimulation [15]. Although 17β-
estradiol (E2) treatment of breast cancer cell lines in-
duced cell proliferation in an mTOR dependent manner,
the molecular mechanism underlying mTOR-mediated
ERα signaling in breast cancer remains unclear [16,17].
Our analysis of TCGA breast tumor data revealed that
expression of the mTORC1 activator Rheb strongly corre-
lated with the ERα− phenotype and expression of the
mTORC2 signaling component Rictor, correlated with
ERα+ breast tumor samples. Notably, we observed a posi-
tive correlation between Rictor expression and PgR ex-
pression levels in the Luminal B molecular subtype. Based
on these findings, we investigated the molecular role for
mTOR in ERα signaling regulation in breast cancer.
Results
mTOR complex 2 signaling correlates with ERα positive
breast tumor samples
mTOR signaling is emerging as a prominent mediator of
cancer progression enhancing both proliferation and
metastasis [4,5]. Due to the divergent roles played by
mTOR signaling complexes mTORC1 and mTORC2 we
sought to determine the expression levels of key mTOR
signaling components in a cohort of breast cancer tumorsamples. The Cancer Genome Atlas (TCGA) deep se-
quencing data of breast cancer invasive carcinoma gene
expression (IlluminaHiSeq) was analyzed and viewed in
the UCSC Cancer Genomics Browser [18-21]. The ERα
gene signature was used to filter expression levels in
tumor samples (either ERα-positive or ERα-negative)
and the mTOR associated genes Rictor, Raptor, Rheb,
TSC1, TSC2, and mTOR were analyzed. Results demon-
strate that Rictor, TSC1, and TSC2 (all activators of
mTORC2 signaling) have higher expression levels in ERα+
tumor samples compared to ER− (Figure 1A). Interest-
ingly, mTORC1 signaling components had varied expres-
sion with respect to ERα expression. Rheb had high
expression levels correlating to ER− tumors while Raptor
demonstrated higher expression levels in ERα+ tumors
(Figure 1A). There was no observed correlation for mTOR
expression with either an ERα+ or ERα− breast cancer
phenotype. As both Raptor and Rictor show a positive
correlation with ERα expression we then used the Breast
Cancer Gene Expression Miner v3.0 and further examined
the correlation between Raptor or Rictor expression with
ERα expression [22]. Positive correlations for both Rictor
and Raptor with ERα expression were observed, however
there was a stronger correlation between Rictor and ERα
(Pearson’s correlation coefficient r = 0.32) than Raptor
and the ERα (Pearson’s correlation coefficient r = 0.20)
(Additional file 1: Figure S1A and Additional file 1:
S1B). As TSC1/TSC2 complex is an activator of
mTORC2 signaling and a repressor of mTORC1 and
Rheb is an activator of mTORC1 signaling, this data
suggests that mTORC2 signaling may be more promin-
ent in ERα+ and mTORC1 signaling may be more
prevalent in ERα− breast carcinomas.
We previously demonstrated that miRNA expression
was a target of IGF/AKT signaling [23] suggesting a po-
tential for miRNA crosstalk in the regulation of mTOR
signaling. This led us to next test if miRNAs could rep-
resent regulators of the differential expression profiles of
the mTORC signaling components. To examine the mo-
lecular mechanism underlying loss of Rictor and Raptor
expression observed in ERα− breast tumors, putative
miRNA target sites in the 3’UTR of both genes were an-
alyzed using TargetScan6.0. Analysis of highly conserved
miRNAs demonstrated that while several binding sites
for multiple miRNAs were apparent in the 3’UTR of Ric-
tor, Raptor appeared to be targeted by only five highly
conserved miRNAs (Additional file 2: Tables S1 and
Additional file 3: Table S2). Due to the potential for
more miRNAs to target Rictor, we therefore investigated
miRNAs predicted to target Rictor in an ERα+ breast
cancer cell line. The miRNAs (miR-203, miR-194, miR-
98, let-7 g, and miR-155) predicted to have seed sites in
the 3’UTR of Rictor were stably over expressed in the
ERα+ MCF-7 cell line and screened by qPCR for Rictor
Figure 1 mTORC1 activation is Associated with an ER Negative Breast Tumor Phenotype. Deep sequencing data obtained from TCGA data
portal was analyzed with respect to ERα (either ERα positive or negative) status for expression of (A) mTOR associated gene sets (mTOR, TSC1,
TSC2, Rheb, Rictor, Raptor, Rheb) and (B) miR-155 host gene (HG) expression. Heat mat depicts high expression (red, +1) and low expression
(green, −1). Platform analyzed was TCGA breast invasive carcinoma gene expression IlluminaHiSeq n = 1032. Analysis was sorted based on ERα
gene Signature where positive for ER = orange and negative for ER = blue. (C) MCF-7-vector and –miR-155 cells were harvested for qPCR analysis
for mTOR associated genes Rictor, TSC1, Deptor, Rheb, Raptor, and p70s6 kinase. Ct values were normalized to β-actin and MCF-7-vector cells
designated as 1. * p < 0.05 for n ≥ 3. (D) MCF-7-vector and –miR-155 cells were harvested for western blot analysis for total and phospho-mTOR
(S2448) and mTOR associated proteins Rictor, Raptor, TSC1, and p-70 s6 kinase. Expression normalized to RHO-GDIα, n ≥ 3. (E) MCF-7-vector and
miR-155 cells were harvested for western blot analysis for phosphorylation of downstream mTORC1 associated proteins p-eIF4B (S422), p-S6
ribosomal protein (S235/236), p-p70s6 kinase (Thr389), p-eEF2K (S366). Expression was normalized to RHO-GDIα, n = 2. (F) qPCR of MCF-7-vector
and miR-155 cells for downstream mTORC2 regulated gene PKCα, normalization was to β-actin and vector designated as 1, n = 3.
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miRNA well known for playing various roles in cancer,
was capable of significantly inhibiting Rictor expression
(Additional file 4: Figure S2A).
miR-155 enhances mTOR activity by targeting members
of AKT/mTOR signaling pathway
To better evaluate a role for miR-155 expression with re-
spect to mTOR signaling and the ERα gene signature,
we next analyzed expression of the miR-155 host gene
(miR-155HG) across TCGA tumor data. In opposition to
Rictor expression, the miR-155HG, which encodes the
mature miR-155 sequence, correlated with an ERα− sta-
tus in TCGA breast tumor samples and mature miR-155
expression correlated with an ERα− status in breast can-
cer cell lines (Figure 1B and Additional file 4: Figure
S2B). As miR-155 expression correlated an ERα− pheno-
type and Rictor expression correlated with ERα+ tumors,
we next investigated whether the observed high levels ofmiR-155 expression in ERα− breast cancers was a driving
force for the repression of Rictor. The MDA-MB-157
breast cancer cell line demonstrated the highest levels of
miR-155 expression (Additional file 4: Figure S2B), so
we chose this cell line and transfected a doxorubicin
inducible red fluorescent protein (RFP)-miR-155sponge
designed to inhibit miR-155 expression. Following trans-
fection and RFP induction, we performed qPCR to deter-
mine Rictor expression levels. qPCR was performed and
results demonstrated an increase (p < 0.06) in Rictor ex-
pression levels following miR-155 inhibition (Additional
file 4: Figure S2C). In order to investigate the relation-
ship between miR-155, mTOR, and ERα signaling; we
used the ER+ MCF-7 cell line transfected with miR-155
as this cell line demonstrated repressed Rictor expres-
sion levels and expressed levels of miR-155 equivalent to
that of ER− cell lines (Additional file 4: Figure S2A and
S2D respectively). To better understand the relationship
between miR-155 expression and the mTOR signaling
Table 2 mTOR Associated miR-155 Target Sequences
Expressed in MCF-7 Brest Cancer Cells
Gene Isoforms MCF-7 isoforms
with miR-155
target sites
8-mer
sites
7-mer1A
sites
7-mer8
sites
Rheb 1 1 0 1 0
TSC1 8 3 0 1 0
p70s6K 6 5 1 0 1
Rictor 5 3 1 0 1
PRKAA2 1 1 1 0 1
PML 17 3 0 0 1
EEF2 1 1 0 1 0
Deptor 2 2 0 1 0
EIF4E 4 3 0 1 0
ULK2 2 1 0 1 0
YWHAE 4 4 0 0 1
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Pathway Interaction Database (PID) [24] and obtained
network maps for predicted miR-155 target genes and
pathways (Table 1). Strikingly, many of these pathways
were mediated by PI3K signaling or growth factors,
which have been shown to crosstalk with mTOR signal-
ing and indeed many components of both mTOR signal-
ing complexes (mTORC1 and 2) were, predicted targets
of miR-155 (Table 1) [25].
Given that the TCGA tumor data demonstrated an in-
verse relationship between the loss of Rictor expression
and miR-155HG expression in relation to ERα status
and that Rictor expression was repressed in our MCF7-
miR155 cell line, we next sought to determine the effects
of miR-155 on mTOR signaling. By combining our in-
house Seedfinder program (identifies isoform specific
seedsites across the genome for miR-155) with previ-
ously published deep sequencing data for MCF-7 cells
and the UCSC Genome Browser [26,27]. Appropriate
miR-155 targets were chosen for further investigation
based on evaluation of isoforms with 3’UTR being
expressed in MCF-7 cell line (Table 2). We determined
that the p70s6K 3’UTR possessed an 8-mer site its
3’UTR and the 3’UTRs of Deptor, Rheb, and TSC1 each
possessed 7-mer sites (Table 2). Based on this, qPCR
was performed for Deptor, Rheb, TSC1, Raptor, and
p70s6K. Results demonstrate that in MCF-7-miR-155
cells, significantly increased p70s6 kinase expression
was observed (Figure 1C), and significantly decreasedTable 1 Pathways Predicted to be altered by miR-155
Target Regulation
Pathway p value
PDGFR-beta signaling pathway 2.77E-11
TGF-beta receptor signaling 1.74E-09
Signaling events mediated by hepatocyte
growth factor receptor (c-Met)
6.00E-09
IL4-mediated signaling events 9.61E-08
CXCR4-mediated signaling events 2.22E-08
mTOR signaling pathway 4.37E-08
IGF1 pathway 7.71E-08
Regulation of retinoblastoma protein 9.30E-08
Signaling events mediated by stem cell
factor receptor (c-Kit)
2.75E-07
AP-1 transcription factor network 2.76E-07
ErbB1 downstream signaling 3.70E-07
Neurotrophic factor-mediated Trk receptor signaling 5.56E-07
Direct p53 effectors 5.80E-07
FGF signaling pathway 6.75E-07
GMCSF-mediated signaling events 7.06E-07
p value determined by size of miR-155 target data set, number of molecules in
a pathway, and number of molecules in database. Determines probability that
miR-155 targets are biased towards a particular pathway.expression of the mTOR repressor Deptor was seen
(Figure 1C). Western blot analysis further confirmed
increased mTOR activity demonstrated through the in-
creased total and phospho-mTOR (S2448) in MCF-7-
miR-155 cells (Figure 1D). In addition, decreased Rictor
and TSC1 protein levels were observed in MCF-7-miR-155
cells (Figure 1D). The combined loss of Rictor (a critical
mTORC2 component) and TSC1an mTORC2 activator
and mTORC1 suppressor) suggests that miR-155 induced
mTOR signaling through the mTORC1 complex. Evalu-
ation of downstream targets of mTORC1 and mTORC2
were next evaluated. Western blot demonstrated enhanced
phosphorylation of p-eEF2K and p-eIF4B downstream tar-
gets of mTORC1 (Figure 1E), there was however no no-
ticeable change in p-p70s6K or p-S6 ribosomal protein.
mTORC2 is known to enhance PKCα expression, so we
next evaluated PKCα gene expression and saw repressed
expression of PKCα in the MCF-7-miR-155 cell line
(Figure 1F).
Stable expression of miR-155 disrupts ERα signaling in
MCF-7 breast cancer cells
As crosstalk between mTOR signaling and ERα has been
reported [13,14], it was of interest to investigate a pos-
sible role for miR-155 in ERα signaling. We performed
qPCR with an ERα-responsive and breast cancer associ-
ated genes qPCR gene array. Aberrant basal expression
of ERα-regulated genes was observed in the MCF7-miR-
155 cell line compared to vector. Altered genes included
PgR (a known target of ERα and mTOR signaling) and
PLAU (both decreased) and BCL2, ERBB2, TFF1, and
SERPINA3 (all increased) (Figure 2A and Figure 2B
respectively). This striking divergent expression of
ERα-regulated genes suggested that miR-155 acts as a
possible regulator of estrogen-mediated signaling. To
Figure 2 Overexpression of miR-155 selectively alters estrogen stimulated gene expression of ER-regulated genes in vitro. (A-B) Gene
panel array for ER regulated and cancer associated genes, n = 2. (A) Down regulated genes and (B) up regulated genes (logarithmic scale) in
MCF-7-miR-155 cells compared to vector control. Results represent average fold change ± SEM. (C-F) QPCR was performed for genes, n = 5
(C) PgR, (D) SDF-1, (E) BCL2, and (F) SERPINA3. Cells were grown in 5% CS phenol free DMEM for 48 hours before treatment with DMSO or E2
(1nM) for 24 hours. Cycle number was normalized to beta actin and MCF-7-vector control cells treated with DMSO scaled to 1. Bars represent
average fold change ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.
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starved for 48 hours, treated with 17-α estradiol (E2, 1
nM) or vehicle for 24 hours, and ERα target genes
(PgR, SDF-1, BCL2, and SERPINA3) were analyzed by
qPCR. As previously observed in our gene panel array,
significantly decreased basal PgR mRNA levels were
observed in MCF-7-miR-155 cells compared to MCF-7-
vector (Figure 2C). Basal expression of SDF-1 was also
significantly lower in our MCF-7-miR-155 cell line
(Figure 2D). Basal expression levels of BCL2 and SER-
PINA3 were significantly increased in MCF-7-miR-155
cells and E2 treatment further induced expression of
both genes compared to MCF-7-vector cells (Figure 2E
and Figure 2F respectively). E2 stimulation failed to in-
crease PgR expression levels in MCF-7-miR-155 cell
line to that of basal levels observed in the MCF-7-
vector cell line. It should be noted that PgR, along with
SDF-1, BCL2, and SERPINA3 were all increased following
E2 stimulation; however, PgR alone remained significantlyrepressed following E2 stimulation. Based on these results,
we conclude that overexpression of miR-155 in ERα+
breast cancer cells disrupted E2 signaling but did not
completely inhibit the cellular response to hormone.
miR-155 induced mTOR/ERα crosstalk is not through
direct mTOR induced phosphorylation of ERα
Since PgR was the only E2 responsive gene that
remained significantly repressed and mTOR is a known
mediator of ER signaling both directly and indirectly, we
next set out to further define the effects of miR-155 ex-
pression on mTOR/ERα crosstalk by evaluating ERα ex-
pression levels and PgR protein levels and function.
Following qPCR, there was no difference in basal ERα
mRNA or protein levels observed between the MCF-7-
miR-155 cells versus control (Additional file 5: Figure
S3A and S3B respectively). As mTOR signaling is known
to activate ERα phosphorylation at S167 we next sought
to evaluate ERα phospho-levels for S167. Western blot
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(Additional file 5: Figure S3B), suggesting mTOR acti-
vation is not increasing ERα activity directly. Western
blot revealed basal PgR protein levels were decreased
in MCF-7-miR-155 cells compared to -vector cells
(Additional file 5: Figure S3B). To assess PgR functional
activity, a progesterone response element (PRE)-luciferase
assay was performed. MCF-7-vector and -miR-155 cells
were transfected with a PRE-luciferase construct and
treated with progesterone in a dose dependent manner.
The doses of progesterone (100 nM, 1 μM, 10 μM but not
10 nM) significantly increased PRE activity in MCF-7-
vector cells. MCF-7-miR-155 cells demonstrated lower
levels of PRE activity both basally and after 10 nM pro-
gesterone treatment compared to MCF-7-vector cells
(Additional file 5: Figure S3D). PRE-activity in MCF-7-
miR-155 cells was similar to that of basal unstimulated
levels of MCF-7-vector cells for the 100 nM, 1 μM,
10 μM doses of progesterone. Stimulation of PgR with
10 nM E2 for 24 hours prior to treatment with proges-
terone was similar to progesterone alone, with MCF-7-
miR-155 cells demonstrating a loss of PgR activity
(Additional file 5: Figure S3E). Given the loss of func-
tional PgR in MCF7-miR155 cells compared to -vector
and no observed increase in phospho-ERα (S167) in the
MCF-7-miR-155 cell line, we suggest that miR-155-
induced ERα signaling regulation was due to the loss of
Rictor expression rather than direct ERα-mTORC1 cas-
cade interactions with ERα.miR-155 augments E2-stimulated proliferation in vitro and
in vivo
Because miR-155 altered basal ERα-mediated gene ex-
pression (Figure 2A and Figure 2B) and maintained sup-
pression of the E2 responsive gene PgR (Figure 2C), we
sought to determine the biological consequence of miR-
155-altered E2 stimulation. MCF-7-miR-155 and –vector
cells were serum starved for 48 hours prior to stimula-
tion with 1 nM E2 for 72 hours. Cell proliferation was
assessed using crystal violet assays. Treatment with E2
stimulated proliferation of both the MCF-7-vector and
MCF-7-miR-155 cell lines (Figure 3A); however, E2-
stimulated proliferation was significantly greater in MCF-
7-miR-155 cells versus MCF-7-vector cells (52 ± 11.94%
versus 12.8 ± 2.62%). To determine if the enhanced E2 re-
sponse increased tumorigenesis in vivo, ovariectomized
CB-17/SCID female mice were inoculated with either
MCF-7-vector or -miR-155 cells in the mammary fat pad
(MFP) in the presence of exogenous E2 (0.72 mg pellet,
60 day release) versus placebo. At necropsy (day 28 post
cell injection), final tumor volume was significantly greater
for MCF-7-mir-155 tumors (791.96 ± 137.45 mm3) com-
pared to vector tumors (306.12 ± 44.85 mm3) (Figure 3B).These results together demonstrated in vivo and in vitro
that miR-155 expression enhances estrogen response.
miR-155 inhibition of PgR expression is regulated
through mTORC1 activation
Given that miR-155 induced enhanced E2 stimulated
tumorigenesis and proliferation while simultaneously
repressing PgR we next set out to investigate whether
miR-155 activation of mTORC1 leads to the suppression
of PgR. qPCR analysis was conducted after treatment of
MCF-7-miR-155 with 1 nM E2 and the mTORC1 spe-
cific inhibitor RAD001 (20 nM). qPCR results revealed a
significant increase in PgR expression in MCF-7-miR-
155 cells following the combined RAD001/E2 treatment
and PgR levels were equal to that of MCF-7-vector cells
treated with E2 only (Figure 3C). Additionally, induction
of PgR in MCF-7-miR-155 cells by RAD001 and E2 was
significantly greater than E2 only treatment (Figure 3C).
PgR expression in MCF-7-vector cells treated with both
RAD001 and E2 was not significantly different compared
to E2 treatment alone (data not shown). Collectively, the
data indicated that miR-155 induced regulation of
mTORC1 activity in MCF-7-miR-155 cells inhibited PgR
expression. To validate the activity of RAD001, we per-
formed western blot analysis for the eukaryotic transla-
tion initiation factor 4E binding protein (4E-BP1) and
Akt (S473) phosphorylation levels, downstream effector
and target proteins of the mTORC1 complex. MCF-7-
vector and MCF-7-miR-155 cells were treated with the
mTORC1 specific inhibitor RAD001. As anticipated,
phosphorylation of 4E-BP1 was decreased and Akt, which
is inhibited by mTORC1 activity, was increased in MCF-
7-miR-155 cells following treatment with RAD001
(Additional file 6: Figure S4).
As mTOR signaling is known to require E2 induced
proliferation we next sought to determine if mTOR sig-
naling was involved in the heightened E2 induced
tumorigenesis observed in our MCF-7-miR-155 cells. To
test this CB-17/SCID ovariectomized mice were inocu-
lated with MCF-7-miR-155 cells in the presence of E2
(0.72 mg pellet, 60 day release). Mice were administered
5 mg/kg/day of RAD001 or vehicle daily following palp-
able tumor formation (day 7 post cell injection), and
tumor size was recorded every two to three days until
necropsy on day 25. The inhibitory effect of RAD001
was apparent by day 10 post injections, MCF-7-miR-
155 tumors in vehicle-treated animals increased to
364.15% ± 65.07% mm3 at Day 25 from Day 7 (100%).
In contrast, treatment with RAD001 rapidly decreased
tumor size (78.23% ± 13.77% mm3; Figure 3D), and sig-
nificant inhibition of E2-stimulated tumorigenesis con-
tinued through day 25 post injection (study terminated
due to the large tumor size of the vehicle control group
per approved animal protocol). Taken together these
Figure 3 miR-155 enhanced E2 stimulated proliferation is mediated through altered mTOR signaling in vivo and in vitro. (A) Crystal
violet assay for proliferation of MCF-7-vector and MCF-7-miR-155 cells treated with E2. Cells were grown in 5% CS phenol free DMEM for 48 hours
prior to treatment with E2 (1nM) or vehicle control (DMSO). Each cell line was normalized to the respective vehicle control, n = 4. (B) Tumor volume
for ovariectomized CB-17 SCID female mice injected bilaterally with 5X10^6 MCF-7-vector cells or MCF-7-miR-155 cells, n = 5 animals/group. All animals
were implanted with an E2 pellet (0.72 mg) at day of cell injection. Points represent average tumor volume ± SEM. (C) MCF-7-vector and –miR-155 cells
were harvested for total RNA extraction and PCR was performed for PgR following treatment with E2 (1nM), RAD001 (20nM) + E2, or vehicle control
(DMSO), normalized to MCF-7-vector treated with E2 (1nM). Bars represent fold change ± SEM, n≥ 3. * Significantly different from MCF-7-vector + E2
p < 0.05. (D) Tumor volume for ovariectomized CB-17 SCID female mice injected bilaterally with 5X10^6 MCF-7-miR-155 cells + E2 + RAD001 vs.
MCF-7-miR-155 + E2 given placebo, n = 7. Points represent normalized tumor volume ± SEM. * p < 0.05, ** p < 0.01.
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mTOR-ERα crosstalk in vitro and in vivo.
Luminal B molecular subtypes divergent expression of
mTOR signaling components and PgR expression
As increased activation of mTORC1 is known to medi-
ate PgR expression and we demonstrated that loss of
Rictor expression correlated with an ERα− breast cancer
phenotype, we next sought to determine if there was a
clinical correlation between Rictor or Raptor expression
and loss of PgR expression. Genomic data obtained
through the Breast Cancer Gene Expression Miner v3.0
was analyzed for mTOR signaling components (Rictor,
Raptor, and Rheb), ERα, and PgR[22]. Rheb expression
was included in this analysis as it is an activator of
mTORC1 signaling and demonstrated high expression
levels in the TCGA ERα breast cancer tumors (Figure 1A).
No correlation between Rictor and PgR expression was
observed in either the ERα+ luminal A or basal-like tumor
profiles (Figure 4A and Figure 4B). However, since
MCF-7-miR-155 cell line maintained an ERα+ pheno-
type with altered ERα signaling (evident through loss of
PgR and high levels of TFF1, Figure 2A and Figure 2B),
we next sough to determine the correlation between
Rictor and PgR in a luminal B tumor subtype. As seen
in Figure 4C, Rictor expression significantly correlatedwith PgR expression (Pearson’s correlation coefficient r = 54)
and was inversely related to Raptor expression (Pearson’s
correlation coefficient r = −0.41) in breast cancers possessing
a luminal B subtype.
Discussion
The luminal B breast cancer subtype is classified as
ERα+; however, altered ER signaling is commonly ob-
served along with loss of PgR expression. Additionally
this subtype represents a more aggressive stage of dis-
ease than the luminal A subtype and has the potential to
progress to endocrine resistance and hormone inde-
pendence [13,28,29]. Here we demonstrate a clinical cor-
relation between the mTORC2 signaling component
Rictor and receptor status where Rictor expression cor-
relates positively with expression of both ERα and PgR
expression. Additionally like others, we demonstrate a
link too receptor status and miR-155 expression [30].
Through miR-155 overexpression in the ER+ MCF-7
breast cancer cell line we demonstrate alterations in the
mTOR signaling cascade can result in the loss of PgR
expression without prior growth factor stimulation.
Previous studies have shown loss of PgR expression in
clinical samples is used as an indicator of aberrant
growth factor signaling and the IGF induced AKT/
mTOR signaling pathway is commonly associated with
Figure 4 Rictor expression positively correlates with PgR expression in Luminal B breast cancer molecular subtype. (A-C) Targeted gene
expression correlation analysis for ER, PgR, Rictor, Rheb, and Raptor derived from pooled breast cancer samples obtained from BC-GenExMiner-v3.0.
Correlation maps generated based on breast cancer molecular subtype. (A) luminal A, (B) Basal-like, (C) luminal B.
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itionally inhibition of mTOR signaling has been shown
by others to result in a loss of ERα-mediated gene tran-
scription [15]. While these studies have demonstrated
activation of mTORC1 signaling by IGF as a regulatory
mechanism for PgR repression, our results suggest that
both miR-155 and Rictor may be important mediators
of mTORC1 activity and PgR expression irrespective of
growth factor stimulation. In support, others have
shown loss of Rictor enhanced signaling of mTORC1
while increased expression of Rictor led to in inhibition
of mTORC1-mediated signaling. It was suggested that
these results are due to a change in the availability ofthe mTOR protein for mTORC complex assembly
[31,32]. Our data suggests that loss of Rictor may in-
duce mTORC1 activity and thus PgR suppression, as
we see mTORC1 signaling-dependent inhibition of PgR
expression. This is evident through our in vitro and
in vivo experiments using the mTORC1 specific inhibi-
tor to induce PgR expression following treatment with
E2 and to inhibit E2-stimulated tumorigenesis. Current
studies show a link between mTOR and E2-induced
tumorigenesis and cellular proliferation where RAD001
is capable of suppressing E2-induced tumor growth and
cellular proliferation [15,33]. Additionally a synergistic
relationship exists between treatment of ER+ breast
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in breast cancer cell lines.
Taken together, our data demonstrate a role for a miR-
155-mTOR-ERα signaling axis in the progression of breast
carcinomas towards a hormone independent phenotype
evident through the loss of PgR (Figure 5). Numerous
studies have recently shown that miRNAs can act as me-
diators of ERα signaling, either by direct targeting of ERα
for degradation or through inhibition of molecules pertin-
ent to the ERα pathway [34-36]. Additionally it has re-
cently been demonstrated by Zhang et al. that E2 is a
positive regulator of miR-155 expression in the MCF-7
breast cancer cell line [37]. miR-155 is a frequently
deregulated miRNA in human breast cancers and in-
creases cellular proliferation in breast cancer cell lines
[38]. Our data and others demonstrate increased miR-155
expression correlates with an ERα− status in human
breast tumor subtypes as well as breast cancer cell lines
[30,39,40]. We extend previous studies by showing that
miR-155 expression alters hormone receptor signaling
and expression of the ERα regulated gene, PgR, through
alterations in the mTOR signaling pathway. While pre-
vious studies have demonstrated miR-155 to be an in-
hibitor of mTORC1 signaling through the suppression
of Rheb in macrophages [41], we do not see loss of
Rheb expression in our breast cancer cell line and
instead see an inhibition of mTORC2 signaling com-
ponents. miR-155 has recently be shown to target
multiple aspects of the mTOR signaling cascade, in-
cluding mTORC2 component Rictor; however, our re-
sults are the first to demonstrate miR-155 induced
mTOR/ER crosstalk through enhanced mTOR signalingFigure 5 mTORC1 induced repression of PgR is regulated by miR-155 in
induced regulation of mTOR/ER crosstalk.and Rictor suppression [42]. Additionally our study
shows miR-155 expression induces increased phosphor-
ylation of downstream mTORC1 proteins associated
with translation but not through the classically activated
mTOR/p70s6k pathway. Taken together this suggests miR-
155 inhibition and activation of mTOR components to be
cell line specific. Finally our analysis of clinical data shows
a strong correlation between mTOR and ERα signaling
cross talk in luminal B breast cancer, as this subtype
showed a positive correlation for Rictor and PgR expres-
sion, supporting the need for further molecular studies on
the inverse relationship between Raptor and Rictor in
breast cancer.
Materials and methods
Cells and reagents
MCF-7, MDA-MB-157, and BT-549 human breast cancer
cell lines were acquired from American Type Culture Col-
lection (Manassas, VA). Liquid nitrogen stocks were made
upon receipt and maintained until the start of study. ERE–
luciferase and/or qPCR for ER and PgR were used to con-
firm MCF-7 sustained estrogen responsiveness. Morphology
and doubling times were also recorded regularly to ensure
maintenance of phenotype for all cell lines. Cells were used
for no more than 6 months after being thawed. Cells were
maintained as previously described [43]. RAD001 was pur-
chased from Selleck Chemicals LLC, and 17-beta Estradiol
(E2) from Sigma (Sigma-Aldrich St. Louis, MO).
Animals
4–6 wks. old ovariectomized SCID/CB17 female mice
(Charles River Laboratories; Wilmington, MA) weredependently of growth factor stimulation. Schematic for miR-155
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free environment with food and water ad libitum. Cells
were harvested in the exponential growth phase using a
PBS/EDTA solution and washed. Viable cells (5 × 106)
in 50 μl of sterile PBS suspension were mixed with
100 μl Reduced Growth Factor Matrigel (BD Biosci-
ences, Bedford, MA). Injections were administered into
the mammary fat pad using 27 ½ gauge sterile syringes.
Animals were divided into treatment groups of five
mice each: MCF-7 control vector, MCF-7 control vec-
tor plus E2, MCF-7 cells transduced to overexpress ma-
ture miR-155, MCF-7 cells transduced to overexpress
mature miR-155 plus E2. Placebo or E2 pellets (0.72 mg
of estradiol-17α, 60-day release; Innovative Research of
America; Sarasota, FL) were implanted subcutaneously
in the lateral area of the neck using a precision trochar
(10 gauge). All procedures in animals were carried out
under anesthesia using a mix of isofluorane and oxygen.
RAD001 (Everolimus) (Selleck Chemicals LLC, Houston
TX) was administered as a micro emulsion dissolved in
sugar water as 5 mg/kg/day. Tumor size was measured
every 2–3 days using digital calipers. The volume of the
tumor was calculated using the formula: 4/3π LS2
(L = larger radius; S = shorter radius). Animals were
euthanized by cervical dislocation after exposure to
CO2. Tumors were removed and frozen in liquid nitro-
gen or fixed in 10% formalin for further analysis. All
procedures involving these animals were conducted in
compliance with State and Federal laws, standards of
the U.S. Department of Health and Human Services,
and guidelines established by Tulane University Animal
Care and Use Committee. The facilities and laboratory
animals program of Tulane University are accredited by
the Association for the Assessment and Accreditation
of Laboratory Animal Care.
RNA Extraction and Quantitative Real Time RT-PCR
MCF-7-vector and MCF-7-miR-155 cells were harvested
for total RNA extraction using Qiagen RNeasy RNA
purification system or for microRNA miRNeasy purifica-
tion system per manufacturer’s protocol (Qiagen, Valencia,
CA). Quantity and quality of the RNA and miRNA were
determined by absorbance at 260 and 280 nm using the
NanoDrop ND-1000. 2 ug of total RNA was reverse-
transcribed using the iScript kit (BioRad Laboratories,
Hercules, CA) and qPCR was performed using SYBR-
green (Bio-Rad Laboratories, Hercules, CA). β-Actin, PgR,
ERα, BCL-2, SDF-1, SERPIN3A, Rictor, TSC1, Raptor,
Deptor, p70s6 kinase, and Rheb genes were amplified
n > 3. E2 stimulation experiments, cells were grown in
5% DMEM for 48 hours prior to treatment with 1 nM
E2 or DMSO for 24 hours. RAD001 in vitro experiments
cells were pre-treated for 30 minutes with 20 nM RAD001
followed by 100 pM E2 or DMSO. miRNA was reverse–transcribed using the SABiosciences RT2 miRNA first
strand kit (Qiagen, Valencia, CA) and qPCR was per-
formed using SABiosciences SYBR green, miR-155 pri-
mer, U6 primer, and SA- Bioscience RT2 cancer miRNA
array plate (MAH-102A) were purchased from Qiagen
(Valencia, CA). Data was analyzed by comparing rela-
tive target gene expression to β-actin for mRNA and
U6 for miRNA. Relative gene expression was analyzed
using 2-ΔΔCt method [44].
Transfection of Cell Lines
miR-155 and vector plasmid were generated as previ-
ously described[45]. MCF-7 cells were transfected with
pre-mir-155 or vector plasmid using Lipofectamine 2000
at 1ug/ul OPTI-MEM (Invitrogen, Grand Isles, NY) as
per manufacturer’s protocol. Parental MCF-7 cells were
grown in a 100 mm dish. 5ug pre-mir-155 or vector
plasmid was added to 100 ul serum free opti-MEM then
15 ul Lipofectamine was added. Following 30 minutes
opti-MEM containing plasmid was added to MCF-7 cells.
The following day cells were treated with 300 ng/ml puro-
mycin. Cells were maintained in 10% DMEM and treated
with 300 ng/ml puromycin every two days for 2 weeks.
Colonies were pooled and verification of mature miR-155
overexpression was confirmed using qPCR for mature
miR-155. Stable pools were maintained in 10% DMEM as
described above. For generation of miR-155 sponge, miR-
155 sponge sequence was taken from pMSCV-puro-GFP-
miR155SPONGE as previously described [46] and inserted
downstream from the RFP sequence in the TRIPz-RFP
vector backbone. Sponge was transfected through lenti-
viral transfection as previously described [47] and retro-
virus packing was performed following the manufacturer's
instructions (Thermo ScientificBio, Pittsburgh PA).
Crystal Violet Assay
MCF-7-vector and MCF-7-miR-155 cells grown in 5%
phenol free DMEM for 24 hours and then plated in 48
well plates (7000 cells per well) for 24 hours prior to a
one time treatment with 1 nM E2 or DMSO. After
72 hours cells were washed once with PBS and fixed and
stained using 0.1% Crystal Violet (in 20% methanol) for
10 minutes. Cells were washed with water and lysed with
1% SDS. Gene5 plate reader was used to read absorb-
ance at wavelength 630. Each cell line was normalized to
its respective DMSO treated group.
Western blot analysis
MCF-7-vector and –miR-155 cells grown 10% FBS
DMEM supplemented. Cells were washed with PBS and
lysed with M-Per lysis buffer supplemented with 1% pro-
tease inhibitor and 1% phosphatase inhibitors (I/II)
(Invitrogen, Grand Isles, NY). Supernatant containing
protein extracts was obtained through centrifugation at
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extracted per sample was determined by absorbance at
260 and 280 nm using the NanoDrop ND-1000. Proteins
were heat denatured and 40ug of protein were loaded per
lane on Bis-Tris-nuPAGE gel (Invitrogen, Grand Isles NY).
Protein transfer to nitrocellulose through iBlot and iBlot
transfer stacks as per manufacturer’s protocol (Invitrogen,
Grand Isles, NY). Nonspecific binding was blocked by
incubation in 5% BSA in 1% TBS-T for 1 hour. Over-
night incubation of membrane with primary antibody for
total mTOR, p-mTOR(S2448), Rictor, Raptor, TSC1, total
p70s6kinase, p-4E-BP1(S65), AKT(S473), p-p70s6kinase
(Thr389), p-S6 ribosomal protein (S235/236), p-eIF4B
(S422), p-eEF2K (S366) diluted 1:1,000 (Cell Signaling
Technology, Beverly MA) and PgR and ERα (Santa Cruz
Biotechnology, Santa Cruz, CA) diluted 1:250 at 4 degree
Celsius followed by three fifteen minute washes in 1%
TBS-T. Membrane was incubated for 1 hour in secondary
antibody 1:10,000 dilution (LiCor Bioscience, Lincoln NE)
followed by three ten minute washes in 1% TBS-T. Band
density was determined by LiCor gel imager. Normalization
was to Rho GDIα Santa Cruz Biotechnology, Santa Cruz,
CA) and images were cropped in Microsoft Photoshop.
PRE-luciferase assay
Cells were plated in 24-well plates at a density of 5 × 105
cells/well and allowed to attach overnight. After 18 hours,
cells were transfected for 5 hours in serum free DMEM
with 300 ng of PRE-luciferase plasmid, by using 6 to l of
Effectene transfection reagent (QIAGEN, Valencia, CA)
per microgram of DNA. After 5 hours, the transfection
medium was removed and replaced with phenol red-free
DMEM supplemented with 5% CSFBS containing vehicle,
progesterone (100 nM, 50 nM, or 10 nM), or pretreated
with 1 nM E2 for 30 minutes before treatment with
progesterone (100 nM, 50 nM, or 10 nM) and incu-
bated at 37°C. After 18 h, the medium was removed,
and 100 ul of lysis buffer was added/well and incubated
for 15 minutes at room temperature. Luciferase activity
for the cell extracts was determined using luciferase sub-
strate (Promega, Madison, WI) in an Auto Lumat Plus
luminometer (Berthold, Oak Ridge, TN).
Breast cancer data sources
Breast cancer gene expression deep sequencing was viewed
through the University California Santa Cruz (UCSC)
Cancer Genomics Browser and compiled by The Cancer
Genome Atlas (TCGA) research network [18-21]. The
TCGA dataset used was the breast invasive carcinoma and
it was analyzed for gene expression aligned through the
IlluminaHiSeq system with total tumor samples n = 1032
and gene signature used was receptor status (ERα).
Targeted gene expression correlation analysis for ER,
PgR, Rictor, Rheb, and Raptor was derived from pooledbreast cancer samples obtained from BC-GenExMiner-
v3.0. Correlation maps were then generated based on
breast cancer molecular subtype luminal A, Luminal B,
and Basal-like. “Pooled” data refers to all data sets which
were merged from all studies and converted to a com-
mon scale with normalization as per BC-GenExMiner-
v3.0 designation [22,48].
Statistical analysis
Statistical Analysis was performed using Graph Pad Prism 5.
Student’s t test was used to determine p values and statisti-
cally significant values had a p values of <0.05.
Additional files
Additional file 1: Figure S1. Pearson’s pairwise correlation for all breast
cancer patients with a positive estrogen receptor status. Results obtained
from Breast Cancer Gene-Expression Miner v3.0. (A) ERα and Rictor. N = 1,195
Pearson’s correlation coefficient (r) = 0.32 (B) ERα and Raptor. N = 1,220.
Pearson’s correlation coefficient (r) = 0.20.
Additional file 2: Table S1. Conserved miRNA predicted to target 8mer
seed site in Rictor 3’UTR.
Additional file 3: Table S2. Conserved miRNA predicted to target 8mer
seed site in Raptor 3’UTR.
Additional file 4: Figure S2. miR-155 Regulates Rictor Expression in
breast cancer cell lines (A) QPCR for Rictor expression levels in MCF-7 cells
stably transfected with miRNA predicted to target 3’UTR of Rictor. (B)
qPCR for miR-155 expression in ER- breast cancer cell lines, y-axis scaled
to log scale. (C) qPCR for Rictor expression following stable transfection
of miR-155 sponge or pmscv-vector in MDA-MB-157 cell line. (D)
qPCR for miR-155 expression in MCF-7 cells stably transfected with
pmscv-miR-155 or vector plasmid, y-axis scald to log scale. Error bars
represent SEM. *** p < 0.001.
Additional file 5: Figure S3. mTOR regulation of ER signaling in
MCF-7-miR-155 cell line is not through direct phosphorylation of ERα
MCF-7-miR-155 and MCF-7-vector cells were harvested for (A) qPCR for ERα
expression levels and (B) western blot analysis of total ERα, phospho-ERα
S167 and total PgR. Values normalized to Rho GDIα. Blot representative of
three. (C) PRE-Luciferase was performed for MCF-7-vector and –miR-155 cells
were treated with vehicle (DMSO) or progesterone in a dose dependent
manner for 18 hours. (D) PRE-luciferase of MCF-7-vector and MCF-7-miR-155
cells pretreated with E2 (10 nM) for 30 minutes prior to 18 hours of
stimulation with progesterone in a dose dependent manner. Bars
represent fold change ± SEM of triplicate experiments. *, p < 0.05.
Additional file 6: Figure S4. Rad001 inhibition of mTOR signaling in
MCF-7-miR-155 cells. Western blot analysis of MCF-7-miR-155 for p-4E-BP1
and p-Akt S473 following 6hrs treatment with RAD001 (20 nM) or vehicle
(DMSO). Blot representative of four.
Abbreviations
3’UTR: 3 Prime Untranslated Region; AKT: Cellular Homolog of Murine
Thymoma Virus Akt8 Oncogene; AMPK: 5’AMP-Activated Protein Kinase;
BCL2: B-Cell CLL/Lymphoma 2; DEPTOR: DEP Domain Containing
mTOR-Interacting Protein; DMEM: Dulbecco’s Modified Eagle Medium;
E2: 17β-Estradiol; ERα: Estrogen Receptor alpha; ERBB1: Epidermal Growth
Factor Receptor; PRE: Progesterone Response Element; ERK1/2: Extracellular
Signal Regulated Kinase 1/2; IGF: Insulin-Like Growth Factor; MAPK: Mitogen
Activated Protein Kinase; MCF-7: Michigan Cancer Foundation 7; miRNA:
Micro-Ribonucleic Acid; mTOR: Mammalian Target of Rapamycin; mTORC1: mTOR
Complex 1; mTORC2: mTOR Complex 2; Ovex: Ovariectomized; PgR: Progesterone
Receptor; PI3K: Phosphoinositol (PI) 3-Kinase; PLAU: Plasminogen Activator,
Urokinase; qPCR: Quantitative Real Time RT-Polymerase Chain Reaction;
RAD001: Everolimus; Raptor: Regulatory Associated Protein of TOR; Rictor: RPTOR
Independent Companion of mTOR Complex 2; Rheb: Ras Homolog Enriched In
Martin et al. Molecular Cancer 2014, 13:229 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/229Brain; p53: Tumor Protein p53; SDF-1: Stromal Cell-Derived Factor 1;
SERPINA3: Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase;
Antitrypsin: Member 3; TCGA: The Cancer Genome Atlas; TFF1: Trefoil Factor 1;
TSC1: Tuberous Sclerosis Complex 1; TSC2: Tuberous Sclerosis Complex 2.
Competing interests
The authors declare that they have no competing interest.
Authors’ contribution
ECM: Performed western blot, crystal violet assay, analysis of TCGA and
BC-GenExMiner tumor data, and drafting of manuscript. LVR: performed
animal studies. SE: performed PRE-luciferase. AEK: performed RNA extraction
and qPCR. KPN: performed manuscript revision, editing, and intellectual input.
EKF: performed plasmid construction, lentiviral preparation, and intellectual
input. BMCB: performed manuscript revision. MEB: performed manuscript
revision and conceptual design of experiments. All authors read and approved
the final manuscript.
Grant support
This research was supported by National Institutes of Health- CA125806, The
Office of Naval Research N00014-16-1-1136 (ME Burow) and National Center
for Research Resources P20RR020152 and The Department of Defense Breast
Cancer Research Program BC085426 (BM Collins-Burow), NCI-U54 CA113001-07
Epigenetic Changes in Cancer Genomes (The Integrative Cancer Biology
Program (ICBP): Centers for Cancer Systems Biology (CCSB) (KP Nephew),
National Institutes of Health grants R01CA138268, R01AI106676, and
R01AI101046 (EK Flemington).
Author details
1Department of Medicine-Section of Hematology and Medical Oncology,
Tulane University, New Orleans, LA, USA. 2Department of Pharmacology,
Tulane University, New Orleans, LA, USA. 3The Center for Bioenvironmental
Research, Tulane University, New Orleans, LA, USA. 4Department of
Pathology, Tulane University, New Orleans, LA, USA. 5Medical Sciences and
Department of Cellular and Integrative Physiology, Indiana University School
of Medicine, Bloomington, IN, USA.
Received: 28 May 2014 Accepted: 24 September 2014
Published: 6 October 2014
References
1. Dunlop EA, Tee AR: Mammalian target of rapamycin complex 1:
signalling inputs, substrates and feedback mechanisms. Cellular signalling
2009, 21:827–835.
2. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E,
Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N:
mTORC1-mediated cell proliferation, but not cell growth, controlled by
the 4E-BPs. Science 2010, 328:1172–1176.
3. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY,
Weiss HL, O'Connor KL, Gao T, Evers BM: mTORC1 and mTORC2 regulate
EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1
signaling pathways. Cancer research 2011, 71:3246–3256.
4. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes &
development 2004, 18:1926–1945.
5. Kim J, Kundu M, Viollet B, Guan KL: AMPK and mTOR regulate autophagy
through direct phosphorylation of Ulk1. Nature cell biology 2011,
13:132–141.
6. Sengupta S, Peterson TR, Sabatini DM: Regulation of the mTOR complex 1
pathway by nutrients, growth factors, and stress. Molecular cell 2010,
40:310–322.
7. Huang J, Manning BD: A complex interplay between Akt, TSC2 and the
two mTOR complexes. Biochemical Society transactions 2009, 37:217–222.
8. Huang J, Dibble CC, Matsuzaki M, Manning BD: The TSC1-TSC2 complex is
required for proper activation of mTOR complex 2. Molecular and cellular
biology 2008, 28:4104–4115.
9. Huang J, Wu S, Wu CL, Manning BD: Signaling events downstream of
mammalian target of rapamycin complex 2 are attenuated in cells and
tumors deficient for the tuberous sclerosis complex tumor suppressors.
Cancer research 2009, 69:6107–6114.10. Julien LA, Carriere A, Moreau J, Roux PP: mTORC1-activated S6K1
phosphorylates Rictor on threonine 1135 and regulates mTORC2
signaling. Molecular and cellular biology 2010, 30:908–921.
11. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A,
Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J,
Pandolfi PP: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. The Journal
of clinical investigation 2008, 118:3065–3074.
12. Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53
and mTOR pathways in cells. Proceedings of the National Academy of
Sciences of the United States of America 2005, 102:8204–8209.
13. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone
receptor loss in breast cancer and its implications for endocrine therapy.
Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2005, 23:7721–7735.
14. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV: Insulin-like
growth factor-I inhibits progesterone receptor expression in breast
cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target
of rapamycin pathway: progesterone receptor as a potential indicator of
growth factor activity in breast cancer. Molecular endocrinology 2003,
17:575–588.
15. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D: The IGF pathway regulates
ERalpha through a S6K1-dependent mechanism in breast cancer cells.
Molecular endocrinology 2011, 25:516–528.
16. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S,
Lane HA: Dual inhibition of mTOR and estrogen receptor signaling
in vitro induces cell death in models of breast cancer. Clinical cancer
research : an official journal of the American Association for Cancer Research
2005, 11:5319–5328.
17. Chang SB, Miron P, Miron A, Iglehart JD: Rapamycin inhibits proliferation
of estrogen-receptor-positive breast cancer cells. The Journal of surgical
research 2007, 138:37–44.
18. Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, Ma S, Wilks
C, Stuart J, Haussler D, Zhu J: The UCSC Cancer Genomics Browser:
update 2013. Nucleic acids research 2013, 41:D949–954.
19. Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ,
Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D,
Zhu J: The UCSC Cancer Genomics Browser: update 2011. Nucleic acids
research 2011, 39:D951–959.
20. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM:
Inference of patient-specific pathway activities from multi-dimensional
cancer genomics data using PARADIGM. Bioinformatics 2010, 26:i237–245.
21. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J,
Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T: The UCSC Cancer
Genomics Browser. Nature methods 2009, 6:239–240.
22. Jezequel P, Frenel JS, Campion L, Guerin-Charbonnel C, Gouraud W, Ricolleau
G, Campone M: bc-GenExMiner 3.0: new mining module computes breast
cancer gene expression correlation analyses. Database: the journal of
biological databases and curation 2013, 2013:bas060.
23. Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM,
Burow ME: Insulin-like growth factor-1 signaling regulates miRNA
expression in MCF-7 breast cancer cell line. PloS one 2012, 7:e49067.
24. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH:
PID: the Pathway Interaction Database. Nucleic acids research 2009,
37:D674–679.
25. Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J,
Shen K: Dual inhibition of PI3K and mTOR mitigates compensatory AKT
activation and improves tamoxifen response in breast cancer. Molecular
cancer research : MCR 2013, 11:1269–1278.
26. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans
M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR,
Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR,
Clawson H, Barber GP, Haussler D, Kent WJ: The UCSC Genome Browser
database: update 2010. Nucleic acids research 2010, 38:D613–619.
27. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF,
Schroth GP, Burge CB: Alternative isoform regulation in human tissue
transcriptomes. Nature 2008, 456:470–476.
28. Creighton CJ: The molecular profile of luminal B breast cancer. Biologics:
targets & therapy 2012, 6:289–297.
29. Kim HJ, Cui X, Hilsenbeck SG, Lee AV: Progesterone receptor loss
correlates with human epidermal growth factor receptor 2
Martin et al. Molecular Cancer 2014, 13:229 Page 13 of 13
http://www.molecular-cancer.com/content/13/1/229overexpression in estrogen receptor-positive breast cancer. Clinical cancer
research: an official journal of the American Association for Cancer Research
2006, 12:1013s–1018s.
30. Lu Z, Ye Y, Jiao D, Qiao J, Cui S: Liu Z: miR-155 and miR-31 are differentially
expressed in breast cancer patients and are correlated with the estrogen
receptor and progesterone receptor status. Oncology letters 2012, 4:1027–1032.
31. Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y,
Hay N: FoxOs inhibit mTORC1 and activate Akt by inducing the
expression of Sestrin3 and Rictor. Developmental cell 2010, 18:592–604.
32. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H,
Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a
rapamycin-insensitive and raptor-independent pathway that regulates
the cytoskeleton. Current biology : CB 2004, 14:1296–1302.
33. Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA: New hypotheses
and opportunities in endocrine therapy: amplification of oestrogen-
induced apoptosis. Breast 2009, 18(Suppl 3):S10–17.
34. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ:
MicroRNA-18a prevents estrogen receptor-alpha expression, promoting
proliferation of hepatocellular carcinoma cells. Gastroenterology 2009,
136:683–693.
35. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M,
Croce CM, Nephew KP: MicroRNA-221/222 confers breast cancer
fulvestrant resistance by regulating multiple signaling pathways.
Oncogene 2011, 30:1082–1097.
36. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ:
MicroRNA-221/222 negatively regulates estrogen receptor alpha and is
associated with tamoxifen resistance in breast cancer. The Journal of
biological chemistry 2008, 283:31079–31086.
37. Zhang C, Zhao J, Deng H: 17beta-estradiol up-regulates miR-155
expression and reduces TP53INP1 expression in MCF-7 breast cancer
cells. Molecular and cellular biochemistry 2013, 379:201–211.
38. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED: MicroRNA-
155 functions as an OncomiR in breast cancer by targeting the
suppressor of cytokine signaling 1 gene. Cancer research 2010,
70:3119–3127.
39. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ:
MicroRNA-155 regulates cell survival, growth, and chemosensitivity by
targeting FOXO3a in breast cancer. The Journal of biological chemistry
2010, 285:17869–17879.
40. Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of
microRNA aberrant expression in tissues and sera from patients with
breast tumor. Gynecologic oncology 2010, 119:586–593.
41. Wang J, Yang K, Zhou L, Minhaowu A, Wu Y, Zhu M, Lai X, Chen T, Feng L,
Li M, Huang C, Zhong Q, Huang X: MicroRNA-155 promotes autophagy to
eliminate intracellular mycobacteria by targeting Rheb. PLoS pathogens
2013, 9:e1003697.
42. Wan G, Xie W, Liu Z, Xu W, Lao Y, Huang N, Cui K, Liao M, He J, Jiang Y,
Yang BB, Xu H, Xu N, Zhang Y: Hypoxia-induced MIR155 is a potent
autophagy inducer by targeting multiple players in the MTOR pathway.
Autophagy 2014, 10:70–79.
43. Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM,
Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardy PW,
Beckman BS, McLachlan JA, Cleveland TE, Burow ME: Antiestrogenic
glyceollins suppress human breast and ovarian carcinoma
tumorigenesis. Clinical cancer research : an official journal of the American
Association for Cancer Research 2006, 12:7159–7164.
44. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW:
Quantitative reverse transcription-polymerase chain reaction to study
mRNA decay: comparison of endpoint and real-time methods. Analytical
biochemistry 2000, 285:194–204.
45. Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington
EK: MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates
Epstein-Barr virus-regulated gene expression pathways. Journal of virology
2008, 82:5295–5306.
46. Marsolier J, Pineau S, Medjkane S, Perichon M, Yin Q, Flemington E,
Weitzman MD, Weitzman JB: OncomiR addiction is generated by a
miR-155 feedback loop in Theileria-transformed leukocytes. PLoS
pathogens 2013, 9:e1003222.
47. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME,
Collins-Burow BM: Targeting triple-negative breast cancer cells with thehistone deacetylase inhibitor panobinostat. Breast cancer research: BCR
2012, 14:R79.
48. Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C,
Ricolleau G: Campion L: bc-GenExMiner: an easy-to-use online platform
for gene prognostic analyses in breast cancer. Breast cancer research and
treatment 2012, 131:765–775.
doi:10.1186/1476-4598-13-229
Cite this article as: Martin et al.: microRNA regulation of mammalian
target of rapamycin expression and activity controls estrogen receptor
function and RAD001 sensitivity. Molecular Cancer 2014 13:229.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
